10 Reasons Home Care Agency Sales Fall Through (And How to Prevent Each One)

A signed Letter of Intent feels like the finish line. It is not. Across the home care M&A market, roughly one in three signed LOIs never reaches close. The reasons are remarkably consistent, repeating across personal care, home health, hospice, IDD, behavioral health, and pediatric agencies year after year.

The good news: nearly every deal killer on this list is preventable with the right preparation. Below are the 10 most common reasons home care agency sales fall through — and the specific seller-side actions that prevent each one.

---

1. EBITDA Restatement During Quality of Earnings

What happens: The buyer’s QoE accountants review the financials in detail and produce a normalized EBITDA materially lower than the figure the LOI was based on. The buyer either retrades the purchase price downward, expands the earnout to bridge the gap, or walks.

Why it kills deals: A 10% EBITDA reduction at a 7x multiple equals a 70% reduction in the proceeds gap that needs to be bridged. Sellers often refuse to accept the retrade, and buyers refuse to honor the original number. The deal stalemates and dies.

Prevention:

• Commission a sell-side Quality of Earnings report before market launch
• Document every add-back with primary-source evidence
• Reconcile QuickBooks to tax returns to bank statements before any buyer sees financials
• Avoid aggressive normalization (rent below market, owner comp adjustments without market data)

---

2. Compliance and Licensing Surprises

What happens: The buyer’s healthcare regulatory counsel discovers an unresolved survey deficiency, an open OIG matter, a lapsed state license in a satellite office, an unresolved Medicare audit, or a pattern of HHCAHPS scores below threshold.

Why it kills deals: Regulatory exposure transfers with the agency in most deal structures. Buyers — especially private equity platforms with lender covenants — cannot accept open compliance risk. Curing the issue often takes longer than the buyer’s investment timeline allows.

Prevention:

• Run a pre-sale compliance audit with healthcare regulatory counsel 6–12 months ahead of process launch
• Resolve all open survey citations, OIG inquiries, and licensure issues before going to market
• Disclose remaining items proactively in the CIM with remediation plans
• Maintain a current compliance log accessible in the data room from day one

---

3. Revenue and Referral Concentration

What happens: Diligence reveals that 30%+ of revenue comes from a single payer, a single referral source, a single facility partnership, or a single geographic market. The buyer’s investment committee flags concentration risk and either reprices, restructures with a concentration earnout, or declines to proceed.

Why it kills deals: Concentration represents single-point-of-failure risk that institutional buyers are structurally unable to underwrite at full multiples.

Prevention:

• Quantify and disclose concentration in the CIM upfront — surprises kill, transparency negotiates
• Show diversification trend lines (concentration declining year over year is a positive story)
• Document the depth and resilience of concentrated relationships (length, contracts, succession of contacts)
• If concentration is severe, consider 12–24 months of pre-sale diversification before launch

---

4. Caregiver Turnover and Workforce Issues

What happens: The buyer’s operational diligence identifies caregiver turnover rates above industry benchmark (typically >65–80% annual), an open labor dispute, a recent walkout, or active union organizing. In some markets, the buyer also flags undocumented worker exposure or wage-and-hour irregularities.

Why it kills deals: Workforce instability directly reduces achievable EBITDA multiples. In severe cases, it suggests the post-close business may not deliver the historical financials buyers underwrote.

Prevention:

• Track and report caregiver turnover monthly in a defensible format
• Resolve wage-and-hour exposure with employment counsel before going to market
• Document caregiver retention initiatives (referral bonuses, training programs, recognition)
• Address I-9 compliance proactively across all locations

---

5. Working Capital Disputes

What happens: The buyer’s working capital target (“peg”) comes in materially higher than the seller expected, effectively reducing net proceeds at close by hundreds of thousands — sometimes millions — of dollars. Negotiations stall over the calculation methodology.

Why it kills deals: Working capital is one of the most technically complex and most commonly mishandled areas of home care M&A. A peg dispute that surfaces late in the process consumes negotiating goodwill that the deal needs for closing.

Prevention:

• Build a 12-month trailing working capital analysis before LOI
• Negotiate the peg mechanism (TTM average vs. 6-month average vs. seasonally adjusted) explicitly in the LOI, not the purchase agreement
• Aggressively manage A/R aging in the months leading to close
• Engage M&A counsel and your advisor to model the peg outcome before signing exclusivity

---

6. Buyer Financing Falls Through

What happens: The buyer — frequently a private equity platform — cannot secure the senior debt or unitranche financing on the terms assumed in the LOI. Lender appetite for home care has tightened (after the 80/20 rule, after a referral source change, after an interest rate cycle). The buyer asks for a price reduction or extends the timeline indefinitely.

Why it kills deals: Time is the enemy of every M&A transaction. A financing delay introduces every other deal-killer risk: financial deterioration, key employee departure, market change, seller fatigue.

Prevention:

• Prioritize buyers with demonstrable closing track records in the past 12 months
• Require the LOI to disclose financing structure and lender relationships
• Run a competitive process so a financing failure with one buyer does not end the deal
• Engage your advisor to vet the buyer’s recent close certainty before granting exclusivity

---

7. Performance Decline During Diligence

What happens: The agency’s revenue, census, or EBITDA softens between LOI and close. A referral source slows, a facility contract is not renewed, a clinical leader departs, hours-per-week drops. The buyer either retrades to the new run-rate or walks.

Why it kills deals: The buyer underwrote the LOI to historical performance. A 5–10% decline in the trailing 90 days is enough to trigger a meaningful retrade. Owners distracted by the deal often accelerate this decline by taking their eye off the operating business.

Prevention:

• Maintain operational discipline through close — the deal is not done until wires clear
• Delegate as much diligence response as possible to your advisor and CFO
• Build a 90-day “stay strong” plan with operations leadership before market launch
• Communicate transparently with the buyer about any operating headwind early

---

8. CHOW and Regulatory Approval Timing

What happens: Change of Ownership applications for Medicare, Medicaid, or state licenses take longer than expected. In some states, CHOW timelines stretch past 6 months. The buyer’s exclusivity expires, financing commitments lapse, or the seller’s patience runs out.

Why it kills deals: Long CHOW timelines convert to extended risk windows. Either party may exit before the regulatory approval lands.

Prevention:

• File CHOW applications as early as possible after LOI execution
• Map state-by-state CHOW timing into the deal calendar before signing
• For multi-state agencies, identify the longest-pole state and structure close mechanics around it
• Consider interim management agreements where state law permits

---

9. Buyer-Seller Fit Breakdown

What happens: Cultural and operational misalignment surfaces during diligence. The buyer’s post-close plan diverges sharply from what the seller understood at LOI — major staff reductions, branch closures, payer mix shifts, or rebranding. The seller, particularly when rolling equity or staying on through transition, decides not to proceed.

Why it kills deals: First-time sellers often underweight the post-close vision question at LOI. By diligence, when the divergence becomes concrete, the relationship has already deteriorated.

Prevention:

• Vet buyers on post-close operating philosophy during management presentations, not after LOI
• Speak with founders of agencies the buyer has previously acquired
• Document the agreed post-close vision in the LOI where possible
• Match buyer type to seller goals: a strategic full-exit looks very different from a PE majority recap with rollover

---

10. Seller Cold Feet

What happens: The seller, often a founder, decides emotionally during diligence that they are not ready to sell. The volume and intensity of diligence requests, the realization that the business they built will be transferred, or a personal life event triggers withdrawal.

Why it kills deals: Even when the deal terms are excellent, a seller who is not psychologically prepared can collapse a process at any point — and the legal and reputational cost is significant.

Prevention:

• Spend serious time on the personal “why” before engaging an advisor
• Talk with peers who have completed sales — both those satisfied and unsatisfied with their outcomes
• Model your post-close life: financial, professional, and personal
• Engage a wealth advisor in parallel with M&A advisory so post-close clarity exists before close

---

The Common Thread: Preparation Before Process

Nine of these ten deal killers are addressable months before market launch. The single most reliable predictor of whether a home care agency sale closes is not the buyer, the multiple, or the market — it is how prepared the seller was before the first buyer was contacted.

Sellers who run their process with a specialized advisor, with sell-side QoE in hand, with compliance pre-audited, with working capital modeled, with caregiver metrics defensible, and with a clear post-close vision close their deals at materially higher rates — and at materially better terms when they do.

Talk to Hendon Partners about a confidential pre-sale assessment →

---

Hendon Partners is a sell-side only home care M&A advisory firm specializing in mid-sized, first-time sellers. We have advised on 150+ home-based care transactions across personal care, home health, hospice, IDD, behavioral health, and pediatric home health.